Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247)

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The sphingolipid metabolic pathway controls the balance of bioactive lipids including apoptotic ceramide and proliferative sphingosine 1-phosphate and, therefore, represents a potential source of new therapeutic targets for numerous diseases. Targets, such as sphingosine kinases (SphK), have been extensively studied, and numerous strategies have been used to develop inhibitors against these enzymes. The WO2010078247 patent application shows the development of some novel sphingo-guanidines, including their water soluble salts, as inhibitors of SphK, and for use in treating and/or preventing diseases and disorders related to undesirable ceramidase, ceramidase-related or SphK activity, including cancer and other proliferative diseases. The synthesis of two agents D-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL146) and L-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL351) is described and they have been shown to inhibit SphK activity, be cytotoxic to cancer cells and decrease the migration rate of human prostate (DU145) cells.

Original languageEnglish (US)
Pages (from-to)807-812
Number of pages6
JournalExpert Opinion on Therapeutic Patents
Volume21
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Guanidines
Ceramidases
Sphingosine
Sphingolipids
Ceramides
Enzyme Inhibitors
Metabolic Networks and Pathways
Cell Movement
Prostate
Neoplasms
Salts
Lipids
sphingosine kinase
Water

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

@article{9c52dd2f12c04a44a7ab9397bcdad3cc,
title = "Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247)",
abstract = "The sphingolipid metabolic pathway controls the balance of bioactive lipids including apoptotic ceramide and proliferative sphingosine 1-phosphate and, therefore, represents a potential source of new therapeutic targets for numerous diseases. Targets, such as sphingosine kinases (SphK), have been extensively studied, and numerous strategies have been used to develop inhibitors against these enzymes. The WO2010078247 patent application shows the development of some novel sphingo-guanidines, including their water soluble salts, as inhibitors of SphK, and for use in treating and/or preventing diseases and disorders related to undesirable ceramidase, ceramidase-related or SphK activity, including cancer and other proliferative diseases. The synthesis of two agents D-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL146) and L-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL351) is described and they have been shown to inhibit SphK activity, be cytotoxic to cancer cells and decrease the migration rate of human prostate (DU145) cells.",
author = "Arun Sharma",
year = "2011",
month = "5",
day = "1",
doi = "10.1517/13543776.2011.573787",
language = "English (US)",
volume = "21",
pages = "807--812",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "5",

}

Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). / Sharma, Arun.

In: Expert Opinion on Therapeutic Patents, Vol. 21, No. 5, 01.05.2011, p. 807-812.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247)

AU - Sharma, Arun

PY - 2011/5/1

Y1 - 2011/5/1

N2 - The sphingolipid metabolic pathway controls the balance of bioactive lipids including apoptotic ceramide and proliferative sphingosine 1-phosphate and, therefore, represents a potential source of new therapeutic targets for numerous diseases. Targets, such as sphingosine kinases (SphK), have been extensively studied, and numerous strategies have been used to develop inhibitors against these enzymes. The WO2010078247 patent application shows the development of some novel sphingo-guanidines, including their water soluble salts, as inhibitors of SphK, and for use in treating and/or preventing diseases and disorders related to undesirable ceramidase, ceramidase-related or SphK activity, including cancer and other proliferative diseases. The synthesis of two agents D-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL146) and L-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL351) is described and they have been shown to inhibit SphK activity, be cytotoxic to cancer cells and decrease the migration rate of human prostate (DU145) cells.

AB - The sphingolipid metabolic pathway controls the balance of bioactive lipids including apoptotic ceramide and proliferative sphingosine 1-phosphate and, therefore, represents a potential source of new therapeutic targets for numerous diseases. Targets, such as sphingosine kinases (SphK), have been extensively studied, and numerous strategies have been used to develop inhibitors against these enzymes. The WO2010078247 patent application shows the development of some novel sphingo-guanidines, including their water soluble salts, as inhibitors of SphK, and for use in treating and/or preventing diseases and disorders related to undesirable ceramidase, ceramidase-related or SphK activity, including cancer and other proliferative diseases. The synthesis of two agents D-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL146) and L-erythro-2-N-(1′-carboxamidino)sphingosine hydrochloride (LCL351) is described and they have been shown to inhibit SphK activity, be cytotoxic to cancer cells and decrease the migration rate of human prostate (DU145) cells.

UR - http://www.scopus.com/inward/record.url?scp=79955112221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955112221&partnerID=8YFLogxK

U2 - 10.1517/13543776.2011.573787

DO - 10.1517/13543776.2011.573787

M3 - Article

VL - 21

SP - 807

EP - 812

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 5

ER -